Efficacy

Zynlonta (loncastuximab tesirine-lpyl) for Lymphoma

Zynlonta, also known by its generic name loncastuximab tesirine-lpyl, is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), DLBCL arising from low grade lymphoma, and also high-grade B-cell lymphoma. The efficacy of Zynlonta was primarily shown in a multicenter, single-arm, open-label trial known as LOTIS-2, which demonstrated a significant therapeutic benefit in this patient population.

In the LOTIS-2 trial, the overall response rate (ORR) to Zynlonta was observed to be approximately 48.3%, with a complete response (CR) rate of 24.1%. The median duration of response (DOR) for those who achieved a CR was 10.3 months, indicating a substantial period of disease control for responders. These results underscore the potential of Zynlonta as an effective treatment option for patients with relapsed or refractory large B-cell lymphoma who have exhausted other treatment avenues.

Darvias (darinaparsin) for Lymphoma

Darvias, known generically as darinaparsin, is a novel organic arsenic compound that has been investigated for its potential use in the treatment of various types of lymphoma, including peripheral T-cell lymphoma (PTCL) and Hodgkin's lymphoma. While Darvias is not currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of lymphoma, clinical trials have been conducted to evaluate its efficacy in this setting. It is important to note that the use of Darvias for lymphoma would be considered off-label, and its efficacy data are derived from limited clinical studies.

In early clinical trials, darinaparsin has shown some promising results in patients with relapsed or refractory lymphoma. However, the available data on the efficacy of Darvias in lymphoma is not as robust as that for approved therapies, and further clinical trials would be necessary to fully establish its therapeutic profile. As such, the current understanding of Darvias' efficacy in lymphoma is preliminary, and healthcare providers may consider its use based on individual patient needs and in the context of clinical trials.